HIV-1 drug-resistant minority variants: Sweating the small stuff

Journal of Infectious Diseases

Volumn 209, Issue 5, 2014, Pages 639-641

  Li, Jonathan Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HIV; minority variants; virologic failure

Indexed keywords

HIV; MINORITY VARIANTS; VIROLOGIC FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE;

EID: 84894287868     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit656     Document Type: Note

References (28)

1. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
2. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168-71.
3. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242:1171-3.
4. Ho DD, Neumann AU, Perelson AS, ChenW, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.Nature 1995; 373:123-6.
5. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
6. Li JZ, Kuritzkes DR. Clinical implications of HIV-1 minority variants. Clin Infect Dis 2013; 56:1667-74.
7. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365:671-3.
8. Church JD, Jones D, Flys T, et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006; 8:430-2; quiz 527.
9. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203:1174-81.
10. Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258-62.
11. Gadhamsetty S, Dixit NM. Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model. J Virol 2010; 84:10230-40.
12. Li JZ, Paredes R, Ribaudo HJ, et al. Lowfrequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305:1327-35.
13. Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 2010; 5: e10952.
14. Fisher R, van Zyl GU, Travers SA, et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 2012; 86: 6231-7.
15. Charpentier C, Laureillard D, Piketty C, et al. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010; 24:867-73.
16. Liu J, Miller MD, Danovich RM, et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 2011; 55:1114-9.
17. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009; 4:e5683.
18. Swenson LC, Mo T, Dong WW, et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203:237-45.
19. Tsibris AM, SagarM, Gulick RM, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008; 82:8210-4.
20. Swenson LC, Mo T, Dong WW, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732-42.
21. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
22. Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, Kunz A. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One 2011; 6:e20357.
23. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 2011; 108:9202-7.
24. Li JZ, Paredes R, Ribaudo HJ, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012; 26:185-92.
25. Lockman S, Hughes M, Sawe F, et al. Nevirapine-versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 2012; 9:e1001236.
26. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-72.
27. Dudley DM, Chin EN, Bimber BN, et al. Low-cost ultra-wide genotyping using roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012; 7:e36494.
28. Kagan RM, Johnson EP, Siaw M, et al. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatmentexperienced patients. PLoS One 2012; 7: e46334.